Novo Nordisk A/S (NYSE:NVO) and Neose Technologies, Inc. (Nasdaq GM: NTEC) announced that Novo Nordisk has completed the initial phase 1 clinical trial with NN7128 (GlycoPEGylated factor VIIa), a long-acting version of NovoSeven® coagulation factor FVIIa (recombinant) administered intravenously.

New Phase III data showed that in patients with multiple lipid problems, Abbott's investigational TriLipix(TM) (ABT-335) combined with AstraZeneca's CRESTOR(R) (rosuvastatin calcium) led to greater improvements than the corresponding monotherapy in treating all three key lipids - LDL "bad" cholesterol, HDL "good" cholesterol and triglycerides.

The European Medicines Agency (EMEA) has been formally notified by Bristol-Myers Squibb Pharma EEIG of its decision to withdraw its application for a centralised marketing authorisation for the medicine DuoCover (fixed-dose combination tablets of 75 mg clopidogrel/75 mg acetylsalicylic acid and 75 mg clopidogrel/100 mg acetylsalicylic acid).

The European Medicines Agency (EMEA) has been formally notified by Sanofi Pharma Bristol-Myers Squibb SNC of its decision to withdraw its application for a centralised marketing authorisation for the medicine DuoPlavin (fixed-dose combination tablets of 75 mg clopidogrel/75 mg acetylsalicylic acid and 75 mg clopidogrel/100 mg acetylsalicylic acid).

Amgen (NASDAQ: AMGN) posted to the company's Web site grants and donations made by the Amgen Medical Education department (AmgenMED) and the Amgen Foundation. The posting is the latest element of Clearly Amgen, a section of the Company's Web site designed to provide clear and easy access to Amgen's policies and practices.

Pfizer Inc announced that Lipitor® (atorvastatin calcium) 80 mg significantly reduced the risk of major cardiovascular events, including heart attack and stroke, by 27 percent in patients with heart disease who had previous coronary bypass surgery compared with patients taking the 10 mg dose of Lipitor.

In the first quarter of 2008, Nycomed’s adjusted EBITDA increased by 6.2% to € 304.0 million compared to € 286.3 million in the first quarter of 2007, benefiting from the cost decreasing effects of last year's restructuring.